Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Open in API
Filings indexed 684 across all filing types
Latest filing 2017-04-04 Director's Dealing
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2017-04-04 English
FORM 4
Director's Dealing
2017-04-04 English
FORM 4
Director's Dealing
2017-04-04 English
Regulatory Filings 2017
Regulatory Filings
2017-03-27 English
S-8
Capital/Financing Update Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC by SCYNEXIS, Inc. on March 13, 2017. It registers additional shares of common stock under the company's 2014 Equity Incentive Plan and Employee Stock Purchase Plan. The document includes details about the securities to be registered, calculation of registration fees, exhibits such as the equity incentive plan and employee stock purchase plan, and signatures of company officers. Form S-8 is a registration statement used to register securities to be offered to employees under employee benefit plans. This is a capital markets filing related to share issuance under employee plans, not a financial report, earnings release, or management discussion. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive content, not just an announcement or certification, so it is not RPA or RNS. Confidence is high due to clear identification of Form S-8 and content.
2017-03-13 English
10-K
Annual Report FY 2016
2017-03-13 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.